Cargando…

Adjuvants influence the maturation of VRC01-like antibodies during immunization

Once naive B cells expressing germline VRC01-class B cell receptors become activated by germline-targeting immunogens, they enter germinal centers and undergo affinity maturation. Booster immunizations with heterologous Envs are required for the full maturation of VRC01-class antibodies. Here, we ex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knudsen, Maria L., Agrawal, Parul, MacCamy, Anna, Parks, K. Rachael, Gray, Matthew D., Takushi, Brittany N., Khechaduri, Arineh, Salladay, Kelsey R., Coler, Rhea N., LaBranche, Celia C., Montefiori, David, Stamatatos, Leonidas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667313/ https://www.ncbi.nlm.nih.gov/pubmed/36405776 http://dx.doi.org/10.1016/j.isci.2022.105473

Ejemplares similares

Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization
por: Parks, K. Rachael, et al.
Publicado: (2019)

Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies
por: Seydoux, Emilie, et al.
Publicado: (2021)

Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain
por: Gray, Matthew D., et al.
Publicado: (2022)

HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2018)

Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies
por: LaBranche, Celia C., et al.
Publicado: (2019)

Germline-targeting HIV-1 Env vaccination induces VRC01-class antibodies with rare insertions
por: Caniels, Tom G., et al.
Publicado: (2023)

Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features
por: Magaret, Craig A., et al.
Publicado: (2019)

Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition
por: Seaton, Kelly E., et al.
Publicado: (2023)

Inference of the HIV-1 VRC01 Antibody Lineage Unmutated Common Ancestor Reveals Alternative Pathways to Overcome a Key Glycan Barrier
por: Bonsignori, Mattia, et al.
Publicado: (2018)

Selection of Peptide Mimics of HIV-1 Epitope Recognized by Neutralizing Antibody VRC01
por: Chikaev, Anton N., et al.
Publicado: (2015)

Germline VRC01 antibody recognition of a modified clade C HIV-1 envelope trimer and a glycosylated HIV-1 gp120 core
por: Borst, Andrew J, et al.
Publicado: (2018)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
por: Mata-Fink, J, et al.
Publicado: (2012)

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials
por: Mkhize, Nonhlanhla N., et al.
Publicado: (2023)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
por: Huang, Yunda, et al.
Publicado: (2021)

Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
por: Huang, Yunda, et al.
Publicado: (2018)

Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound
por: Cale, Evan M., et al.
Publicado: (2020)

Deep sequencing with longitudinal sampling of a VRC01-like-antibody response in a chronically infected individual
por: Zhang, Z, et al.
Publicado: (2012)

Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials
por: Huang, Yunda, et al.
Publicado: (2021)

Linear analysis and differential equations
por: MacCamy, Richard C, et al.
Publicado: (1969)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
por: Lynch, RM, et al.
Publicado: (2012)

Delayed vaginal SHIV infection in VRC01 and anti-α4β7 treated rhesus macaques
por: Calenda, Giulia, et al.
Publicado: (2019)

Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01
por: Cardozo-Ojeda, E. Fabian, et al.
Publicado: (2021)

Characteristics of HIV-1 gp120 molecules that bind ancestor, intermediate and mature forms of VRC01-like antibodies
por: Joyce, M, et al.
Publicado: (2012)

Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies
por: Otsuka, Yuka, et al.
Publicado: (2018)

A systematic analysis of the expression of the anti-HIV VRC01 antibody in Pichia pastoris through signal peptide optimization
por: Aw, Rochelle, et al.
Publicado: (2018)

Expressing anti-HIV VRC01 antibody using the murine IgG1 secretion signal in Pichia pastoris
por: Aw, Rochelle, et al.
Publicado: (2017)

Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection
por: Saha, Ananya, et al.
Publicado: (2020)

A matrix of structure-based designs yields improved VRC01-class antibodies for HIV-1 therapy and prevention
por: Kwon, Young D., et al.
Publicado: (2021)

Improved pharmacokinetics of HIV-neutralizing VRC01-class antibodies achieved by reduction of net positive charge on variable domain
por: Kwon, Young D., et al.
Publicado: (2023)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
por: Huang, Yunda, et al.
Publicado: (2023)

V5 region in the HIV-1 envelope glycoprotein determines viral sensitivity to the broadly neutralizing monoclonal antibody VRC01
por: Guo, D, et al.
Publicado: (2012)

Characterization of VRC01, a potent and broadly neutralizing anti‐HIV mAb, produced in transiently and stably transformed tobacco
por: Teh, Audrey Y‐H., et al.
Publicado: (2013)

Vaccine genetics of IGHV1-2 VRC01-class broadly neutralizing antibody precursor naïve human B cells
por: Lee, Jeong Hyun, et al.
Publicado: (2021)

First-in-human immunoPET imaging of HIV-1 infection using (89)Zr-labeled VRC01 broadly neutralizing antibody
por: Beckford-Vera, Denis R., et al.
Publicado: (2022)

Modified Newcastle Disease virus as an improved vaccine vector against Simian Immunodeficiency virus
por: Manoharan, Vinoth K., et al.
Publicado: (2018)

MicroRNA‐210 Decreases heme Levels by Targeting Ferrochelatase in Cardiomyocytes
por: Qiao, Aijun, et al.
Publicado: (2013)

Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges
por: Khattar, Sunil K., et al.
Publicado: (2015)

Characterization of a Large Panel of Rabbit Monoclonal Antibodies against HIV-1 gp120 and Isolation of Novel Neutralizing Antibodies against the V3 Loop
por: Qin, Yali, et al.
Publicado: (2015)

Structure-guided modification and optimization of antibody VRC07
por: Kwon, Y, et al.
Publicado: (2012)

Comparative Immunogenicity of HIV-1 gp160, gp140 and gp120 Expressed by Live Attenuated Newcastle Disease Virus Vector
por: Khattar, Sunil K., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4r0fhru2u70rg0p235sjgojgch